Molecular Basis of Reduced Glucosylceramidase Activity in the Most Common Gaucher Disease Mutant, N370S
Open Access
- 1 December 2010
- journal article
- Published by Elsevier BV
- Vol. 285 (53), 42105-42114
- https://doi.org/10.1074/jbc.m110.172098
Abstract
No abstract availableThis publication has 63 references indexed in Scilit:
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseThe New England Journal of Medicine, 2009
- Participation of asparagine 370 and glutamine 235 in the catalysis by acid β-glucosidase: The enzyme deficient in Gaucher diseaseMolecular Genetics and Metabolism, 2009
- Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and StabilityBiochemistry, 2009
- Isofagomine Induced Stabilization of GlucocerebrosidaseChemBioChem, 2008
- Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher diseaseProceedings of the National Academy of Sciences of the United States of America, 2007
- Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-β-glucosidaseBiochemical Pharmacology, 2007
- Isofagomine- and 2,5-Anhydro-2,5-imino-d-glucitol-Based Glucocerebrosidase Pharmacological Chaperones for Gaucher Disease InterventionJournal of Medicinal Chemistry, 2006
- The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanismsProceedings of the National Academy of Sciences of the United States of America, 2006
- A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculationsJournal of Computational Chemistry, 2003
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996